Out-of-specification (OOS) results were found for atomoxetine content, below the lower specification limit, and in one batch also non-compliance in the mass uniformity parameter. The risk assessment points mainly to a possibility of reduced treatment effectiveness. Potential effects: absence or reduction of therapeutic efficacy.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use the affected batches of Konaten (Atomoxetine). Patients should consult their doctor or pharmacist to ensure continuity of treatment and to arrange the return of defective packs to the pharm...
The Chief Pharmaceutical Inspector withdrew the specified batches of Konaten from the national market, prohibited their placing on the market, and granted the decision immediate enforceability; previo...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related